Mezavant

Mesalazine, the active ingredient in Mezavant, is a 5-aminosalicylic acid (5-ASA) presented as an oral tablet for systemic use. It is employed to treat ulcerative colitis and related inflammatory conditions in adult patients. GNH USA supplies Mezavant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mezavant belongs to the 5‑ASA class and is used to manage inflammatory bowel disease. - Ulcerative colitis (induction): helps achieve remission of mild‑to‑moderate disease. - Ulcerative colitis (maintenance): supports continued remission and reduces relapse risk. - Proctitis: alleviates localized inflammation of the rectal mucosa.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Abdominal pain: cramping or discomfort in the abdomen. - Headache: transient pain in the head region. - Flatulence: increased intestinal gas. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis, swelling, or difficulty breathing. - Myocarditis: inflammation of the heart muscle. - Pancreatitis: inflammation of the pancreas. - Blood dyscrasias: abnormal blood counts or hemolysis. - Liver enzyme elevation: signs of hepatic injury.

Before initiating therapy, clinicians should consider several safety measures. - Renal monitoring: assess kidney function periodically. - Disease assessment: evaluate ulcerative colitis activity prior to treatment. - Hypersensitivity: avoid in patients with known allergy to mesalazine or related compounds. - NSAID caution: use with non‑steroidal anti‑inflammatory drugs only under supervision. - Store at room temperature: keep in the original pack, protect from moisture.

Mesalazine may interact with other medicines, requiring attention to the interaction level.

Major Interactions (Avoid): - Azathioprine: increased risk of bone‑marrow suppression. - Warfarin: potential enhancement of anticoagulant effect.

Moderate Interactions (Monitor Closely): - Sulfasalazine: additive gastrointestinal irritation. - Metronidazole: possible increase in plasma mesalazine levels. - Oral contraceptives: may reduce hormonal efficacy.